Are there significant clinical differences—pharmacokinetic, safety, weight loss, control of PPG—between the two combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?

Are there significant clinical differences—pharmacokinetic, safety, weight loss, control of PPG—between the two combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?

Are there significant clinical differences—pharmacokinetic, safety, weight loss, control of PPG—between the two combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Juan Frias, FACE, MD

Juan Frias, FACE, MD

Clinical Assistant Professor of Medicine University of California San Diego, California Chief Medical Officer National Research Institute Los Angeles, California